Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Don't kill the parasite: control the disease.

J H Playfair1, J Taverne, C A Bate

  • 1Department of Immunology, University College and Middlesex School of Medicine, London, U.K.

Acta Leidensia
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is tumour necrosis factor really for?

Immunology today·2014
Same author

[Not Available].

Immunology today·2014
Same author

The importance of being nearest.

Immunology today·2014
Same author

[Should elevated beta-HCG levels be an exclusion criteria in clinical trials? A case report of paraneoplastic secretion associated with lung adenocarcinoma].

Revue de pneumologie clinique·2013
Same author

Llamas, lectures and health inspectors on the web.

Parasitology today (Personal ed.)·2006
Same author

ParaSite: The Pick of Parasites on the Web.

Parasitology today (Personal ed.)·2006

Malaria complications are often caused by the body's response, not the parasite itself. Vaccines targeting this response could offer faster protection against severe malaria disease.

Area of Science:

  • Immunology
  • Parasitology
  • Vaccinology

Background:

  • The malaria parasite (blood-stage) is not the direct cause of severe disease complications, except possibly anemia.
  • T cell-deficient mice with lethal infections survive longer, indicating immune-mediated pathology.
  • Clinical observations show children develop immunity to toxic malaria effects before parasite levels decrease.

Purpose of the Study:

  • To investigate the role of host immune response in malaria pathogenesis.
  • To explore the potential of vaccines targeting disease-causing host responses rather than the parasite directly.
  • To identify key molecules involved in malaria-induced toxicity for vaccine development.

Main Methods:

  • Review of laboratory and clinical studies on malaria complications.

Related Experiment Videos

  • Analysis of vaccine efficacy in T cell-deprived mice and studies involving anti-TNF antibodies.
  • Examination of cytokine induction (e.g., tumor necrosis factor) by parasite exoantigens.

    • Main Results:

    • Host immune responses, particularly cytokine production like TNF, contribute significantly to malaria's severe manifestations.
    • Vaccines that do not target parasitemia but modulate immune responses can protect against early mortality.
    • Antibodies blocking TNF can also confer protection against lethal malaria.

    Conclusions:

    • Targeting parasite exoantigens that induce harmful cytokines may lead to effective "anti-disease" vaccines.
    • Such vaccines could confer immunity more rapidly than traditional anti-parasite vaccines.
    • Developing vaccines that block host-mediated toxicity is a promising strategy for malaria control, potentially overcoming challenges of antigenic variation.